ETIB opens clinical trial for patients with HPV-16+ cancers

Posted: Sep 28, 2016

Dr. Christian Hinrichs, Lasker Clinical Research Scholar in the Experimental Transplantation and Immunology Branch, is leading a study of a new therapy for cancers caused by human papillomavirus (HPV), which include cervical, throat, anal, and genital cancers. HPV-related cancer cells carry a protein called E7.  Learn more...

ETIB opens clinical trial for patients with HPV-16+ cancers

Eliminating cancer stem cells: an interview with CCR’s Steven Hou

Posted: Sep 28, 2016

Steven Hou, Ph.D., senior investigator in the Basic Research Laboratory at the Center for Cancer Research describes his latest research that has uncovered potential ways to eliminate cancer stem cells and may offer hope to patients with reoccurring tumors.  Learn more...

Eliminating cancer stem cells: an interview with CCR’s Steven Hou

Swedish Minister for Higher Education & Research visits CCR investigators in Clinical Center

Posted: Sep 27, 2016

The Swedish Minister for Higher Education & Research, Helene Hellmark Knutsson, visited CCR clinical laboratories in the NIH Clinical Center.  Her visit coincided with the signing of a memorandum of understanding with the Department of Health and Human Services to encourage cooperation in promoting cancer advances and joint research opportunities between the two countries.

Swedish Minister for Higher Education & Research visits CCR investigators in Clinical Center

The answer to cancer may be walking beside us

Posted: Sep 27, 2016

Rocky Mountain PBS will air a new documentary this Thursday, Sept. 29 at 9 p.m. called, “The answer to cancer may be walking beside us.” This documentary features Amy LeBlanc, Director of the Comparative Oncology Program, Mark Simpson, Senior Scientist in the Laboratory of Cancer Biology and Genetics, and Chand Khanna, former CCR Senior Scientist. Using animals to study cancer goes hand-in-hand with the Cancer Moonshot goals of accelerating cancer research and making more therapies available to more patients. Vice President Joe Biden, who leads the initiative, says when it comes to cancer, “Time matters. Days matter. Minutes matter.”

The answer to cancer may be walking beside us

CCR celebrates National Postdoc Appreciation Week

Posted: Sep 27, 2016

National Postdoc Appreciation Week took place Sept. 19-23. Throughout the week, outstanding postdocs and training opportunities were featured on Twitter. We’ve recapped our coverage in this Storify post.

CCR celebrates National Postdoc Appreciation Week

Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

Posted: Sep 26, 2016

Thomas Uldrick, senior clinician in the HIV and AIDS Malignancy Branch, has launched a new phase 1 trial evaluating the immunotherapy drug Keytruda, which is designed to target cancer cells in HIV-positive cancer patients. Cancer Today reported that many HIV-positive patients with cancer do not get proper treatment for their cancers, and Uldrick hopes the drug will kill both cancer cells and HIV cells.

Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

Kent Hunter’s circadian gene research highlighted across national news

Posted: Sep 23, 2016

Kent Hunter’s research on breast cancer metastasis and the circadian gene has been covered by Reuters, Fox News and New Scientist. His research suggests that changes to the gene involved in regulating circadian rhythms could influence the metastasis of breast cancer. Hunter is the Deputy Chief of CCR’s Laboratory of Cancer Biology and Genetics.

Kent Hunter’s circadian gene research highlighted across national news

Steven Pavletic discusses new strategies to target GVHD

Posted: Sep 23, 2016

Steven Pavletic, senior clinician in the Experimental Transplantation and Immunology Branch, discussed new strategies for treating graft-versus-host disease with OncLive. He says these new strategies are the result of improved understanding of the disease’s pathophysiology, and the new therapies could lead to less toxic and more effective therapies.  Learn more...

Steven Pavletic discusses new strategies to target GVHD

Pages